Rapport Therapeutics
Rapport Therapeutics, Inc. (Nasdaq: RAPP) is a clinical-stage biotechnology company headquartered in Boston, Massachusetts with research operations in San Diego, California, founded in 2022 and taken public in a $174 million IPO in June 2024. Rapport develops precision small-molecule medicines for central nervous system disorders using its proprietary RAP technology platform, which pairs human genetics with functional proteomics to identify receptor-associated proteins that confer neuroanatomical specificity — the goal being drugs that act only where the disease circuit lives rather than across the whole brain. Its lead clinical candidate, RAP-219, is a selective negative allosteric modulator of TARP-gamma-8-associated AMPA receptors in development for focal onset seizures, peripheral neuropathic pain and bipolar disorder, behind two discovery-stage nicotinic acetylcholine receptor programs targeting alpha-6 (chronic pain) and alpha-9-alpha-10 (hearing disorders). Rapport is a therapeutics developer, not a software vendor: the RAP platform is an internal discovery capability and the company publishes no developer program, no public API and no machine-readable API contract.
Rapport Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Healthcare.
Rapport Therapeutics’ developer surface includes support and 8 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 4
The organization behind the API
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.